Parnaparin is an heparin of low molecular weight with antithrombotic effects.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Parnaparin. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Parnaparin. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Parnaparin. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Parnaparin is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Parnaparin. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Parnaparin. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Obinutuzumab. |
| Rivaroxaban | Parnaparin may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Parnaparin. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Parnaparin. |
| Urokinase | Urokinase may increase the anticoagulant activities of Parnaparin. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Parnaparin. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Parnaparin. |
| Trandolaprilat | The risk or severity of hyperkalemia can be increased when Trandolaprilat is combined with Parnaparin. |
| Moexiprilat | The risk or severity of hyperkalemia can be increased when Moexiprilat is combined with Parnaparin. |
| Cilazaprilat | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Parnaparin. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Parnaparin. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Parnaparin. |
| Quinine | The therapeutic efficacy of Parnaparin can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Parnaparin can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Parnaparin. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Parnaparin. |
| Corticorelin ovine triflutate | The risk or severity of hypotension and sinus node depression can be increased when Parnaparin is combined with Corticorelin ovine triflutate. |
| Oritavancin | The therapeutic efficacy of Parnaparin can be decreased when used in combination with Oritavancin. |
| Streptokinase | Streptokinase may increase the anticoagulant activities of Parnaparin. |
| Telavancin | The therapeutic efficacy of Parnaparin can be decreased when used in combination with Telavancin. |
| Palifermin | The serum concentration of Palifermin can be increased when it is combined with Parnaparin. |
| Pentoxifylline | The therapeutic efficacy of Parnaparin can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Parnaparin. |
| Levocarnitine | The therapeutic efficacy of Parnaparin can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Parnaparin. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Parnaparin. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Parnaparin. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Parnaparin. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Parnaparin. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Parnaparin. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Parnaparin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Parnaparin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Parnaparin. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Parnaparin. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Parnaparin. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Parnaparin. |
| Equol | Equol may decrease the anticoagulant activities of Parnaparin. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Parnaparin. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Parnaparin. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Parnaparin. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Parnaparin. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Parnaparin. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Parnaparin. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Parnaparin. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Parnaparin. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Parnaparin. |
| Estriol | Estriol may decrease the anticoagulant activities of Parnaparin. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Parnaparin. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Parnaparin. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Parnaparin. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Parnaparin. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Parnaparin. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Parnaparin. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Parnaparin. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Parnaparin. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Parnaparin. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Parnaparin. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Parnaparin. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Parnaparin. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Parnaparin. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Parnaparin. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Parnaparin. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Parnaparin. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Parnaparin. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Parnaparin. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Parnaparin. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Parnaparin. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Parnaparin. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Parnaparin. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Parnaparin. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Parnaparin. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Parnaparin. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Parnaparin. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Parnaparin. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Parnaparin. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Parnaparin. |
| Olsalazine | The risk or severity of bleeding can be increased when Parnaparin is combined with Olsalazine. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Parnaparin. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Parnaparin. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Parnaparin. |